- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02324036
The EMPATHy Toolkit: Helping Diabetes Patients Overcome Barriers to Medication Adherence (EMPATHy)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Low income, Mexican American patients with diabetes exhibit high rates of medication nonadherence, which results in poor blood sugar control and serious complications, and often have difficulty communicating their concerns about the medication regimen to physicians. Interventions led by community health workers (CHWs), non-professional community members who are trained to work with patients to improve engagement and communication during the medical visit, have had mixed success in improving outcomes. Although CHWs possess excellent cultural competency and are very effective at establishing rapport with patients, they often lack a sophisticated understanding of all the potential challenges that can come with following a regimen. The primary objective of this project is to develop and pilot test a prototype software toolkit called "EMPATHy" that a CHW can administer to help patients identify and articulate the most important barriers to adherence that they face.
The EMPATHy toolkit will be piloted in an ongoing intervention (Coached Care) in which CHWs are trained to be "Coaches" to meet with patients before the medical visit, and help them prepare a list of important questions for the doctor. The Lead Researcher (Billimek) is a co-director of this intervention program at UCI's Ambulatory Clinics, including the Family Health Center in Santa Ana ,with a highly vulnerable population-low income Mexican American patients with diabetes and a history of nonadherence. A CHW will be trained to use two commercially available software programs configured by the PI to deliver the intervention materials. Patients participating in Coached Care (which is a clinic- based intervention, not a research protocol) will be recruited to (1) complete a Coached Care intervention session that has been modified to incorporate the EMPATHy Toolkit, (2) answer questions about barriers to medication adherence and the feasibility/usability of the software (3) allow the research team to abstract data on the medication regimen and diabetes outcomes (hemoglobin A1c, LDL cholesterol, etc) from the patient's medical record.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Irvine, California, United States, 92697
- Health Policy Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients will be recruited from the University of California Irvine Federally Qualified Health Center family medicine clinic sites in Santa Ana and Anaheim with the following inclusion criteria:
- age 18 and older;
- have poorly controlled type 2 diabetes (as indicated by HbA1c>7.5%, LDL cholesterol >100 mg/dl or systolic blood pressure > 140),
- be of Hispanic ethnicity,
- speak English or Spanish.
These data are available to the research team in an automated report emailed to the lead researcher every week in his role as coordinator of the routine care Coaching program. This report includes a list of upcoming appointments for patients who meet these inclusion criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Coached Care+EMPATHy;
EMPATHy Toolkit: Patient coaching with computer assisted preference assessment
|
Software-based toolkit to help patients identify and prioritize barriers to medication adherence; community health worker provides participation training to patient
|
ACTIVE_COMPARATOR: Routine Coached Care
Patient coaching only
|
Community health worker provides participation training to patient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of a contextualized plan of care (assessed by analyzing an audio recording of the medical visit)
Time Frame: Baseline
|
Development of a contextualized plan of care will be assessed by analyzing an audio recording of the medical visit, using a previously developed coding scheme (see Research Methodology).
If the coder concludes that the plan of care discussed in the visit adequately addresses a contextual factor raised during the visit, it will be determined that a contextualized plan of care was developed.
|
Baseline
|
Attainment of concrete behavioral goal (assessed in a two-week follow-up phone call to the patient)
Time Frame: 2 weeks post visit
|
Attainment of concrete behavioral goal will be assessed in a two-week follow-up phone call to the patient, and will be defined as the patient reporting having completed the specific action that he or she specified with the Coach as a concrete goal during the intervention post-visit.
|
2 weeks post visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Discussion of a contextual factor in the visit (assessed from audio recordings of the visit)
Time Frame: Baseline
|
Discussion of a contextual factor in the visit will be assessed from audio recordings of the visit using a previously developed coding scheme.
If the coder concludes that a relevant barrier to the patient taking his or her medication consistently was raised during the visit, it will be determined that a contextual factor was discussed.
|
Baseline
|
Improvement in "red flag" outcome (assessed from the patient's medical record as the change in the measured value of the outcome measure identified as a high priority outcome)
Time Frame: 6 months post visit
|
Improvement in "red flag" outcome will be assessed from the patient's medical record as the change in the measured value of the outcome measure identified as a high priority outcome ("red flag") from intervention visit date till the next regularly scheduled assessment.
The red flag outcome measure is selected by the Coach and patient during the intervention visit, and can be either hemoglobin A1c, LDL cholesterol or blood pressure level.
|
6 months post visit
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John Billimek, PhD, Irvine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-1442
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on EMPATHy Toolkit
-
Saglik Bilimleri UniversitesiNot yet recruiting
-
Peking UniversityNot yet recruiting
-
University of Illinois at ChicagoCompletedPsychotherapeutic Processes | Transference (Psychology)United States
-
National Taipei University of Nursing and Health...Shin Kong Wu Ho-Su Memorial HospitalCompleted
-
University of MichiganCompletedWomen With BRCA 1 or BRCA 2 Mutation | Non-tested Female Family MembersUnited States
-
Auburn UniversityCompletedBullying of ChildUnited States
-
Sunnybrook Health Sciences CentreScarborough General Hospital; Michael Garron Hospital; York Central Hospital,... and other collaboratorsCompleted
-
The University of Hong KongNot yet recruiting
-
University of TorontoUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; McMaster... and other collaboratorsCompleted
-
Yale UniversityNational Institutes of Health (NIH); National Institute on Aging (NIA); Trinity...CompletedDiabetes Mellitus | DiabetesUnited States